GSK, Amira Team Up In $425 Million Asthma Collaboration
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal gives GSK rights to Amira’s FLAP inhibitors for the treatment of respiratory and cardiovascular disease.
You may also be interested in...
BMS Bets On Amira's IPF Drug In $325M Acquisition
The deal expands BMS's inflammatory disease holdings while bringing double-digit returns to the six-year-old startup's earliest investors.
BMS Bets On Amira's IPF Drug In $325M Acquisition
The deal expands BMS's inflammatory disease holdings while bringing double-digit returns to the six-year-old startup's earliest investors.
Regulus Is On The Launch “Platform” With $20M Series A Financing
Alnylam, Isis keep ownership of joint venture for now, but status change could bring more investors aboard by 2011.